Corporate News
Lucid Diagnostics Inc. (NASDAQ: LUCD) experienced a sharp rally on Monday, 26 September 2026, as its shares surged 25.3 % within a 24‑hour window ending at 01:26 PM Central Europe. At the close of that period, one share was priced at approximately USD 0.41 on the major exchanges. The company’s total supply of shares outstanding stands at 190.9 million, giving it a market capitalization of USD 78.5 million. In the last 24 hours, roughly USD 45.6 million worth of LUCD shares were traded.
Despite this recent uptick, the broader trend over the past month has been negative: the stock has fallen ‑50.95 % since the end of August. Over the longer term, the 200‑day simple moving average sits at USD 1.04, while the 52‑week high of USD 1.63 was recorded on 21 January 2026 and the 52‑week low of USD 0.30 on 22 October 2026. These figures provide context for investors assessing the company’s current valuation and momentum.
Peer Performance in the Last 24 Hours
The performance of Lucid Diagnostics can be compared to several of its peers in the diagnostics and biotechnology space:
| Ticker | 24‑Hour Move | Current Price (USD) | Market Capitalization (USD mn) |
|---|---|---|---|
| NRXS (Neuraxis) | ‑2.63 % | 7.40 | 92.9 |
| IMDX (Insight Molecular Diagnostic) | ‑0.35 % | 2.83 | 92.6 |
| AMTX (Aemetis) | +8.33 % | 1.30 | 93.8 |
| RGP (Connection) | +5.49 % | 2.69 | 93.3 |
| ICCC (Immucell) | ‑1.82 % | 10.25 | 93.1 |
Immucell’s price‑to‑earnings ratio stands at 137.53, highlighting the premium investors are willing to pay for its growth prospects. The mixed movements among peers illustrate a sector that is still navigating post‑pandemic dynamics and regulatory shifts.
Company Overview
Lucid Diagnostics Inc. is a commercial‑stage medical diagnostics technology firm headquartered in New York, United States. The company focuses on developing diagnostic tools and treatment solutions for esophageal conditions, particularly those stemming from chronic heartburn that can progress to esophageal cancer. By offering advanced diagnostic assays, Lucid Diagnostics aims to enable early detection and personalized therapeutic strategies for patients worldwide. Further details on the company’s product pipeline and clinical milestones can be found on its website at www.luciddx.com .
